The content on this site is intended for healthcare professionals only
Prof Linn speaks with ecancertv at SABCS 2016 to discuss the impact of adjuvant bisphosphonate therapy on patients with early stage breast cancer, finding that there was no significant improvement through its addition after 3 years follow up.
Weighing the slight trends of gastrointestinal side effects against lowered risk of bone metastases, Prof Linn considers if 3 years is an adequate follow up to see the full effects of added bisphosphonate therapy, and notes patient concerns over osteonecrosis of the jaw as a side effect of treatment.
These results were first presented in a press conference session, with video coverage available here.
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
The Southeast Asian Breast Cancer Symposium; background, aims and successes
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
